Volume 2, Issue 11, November 2024 ISSN (E): 2938-3765

CHRONIC ANEMIA: PATHOPHYSIOLOGY, DIAGNOSIS, AND MANAGEMENT

Abdakiova Baxtigul Ilhomiddin qizi,
Tashkent Medical Academy

Abstract

Chronic anemia refers to a prolonged reduction in the number of red blood cells or hemoglobin levels, resulting in impaired oxygen delivery to tissues. It often occurs as a complication of chronic diseases such as autoimmune disorders, infections, malignancies, and kidney disease. The pathophysiology of chronic anemia can involve decreased red blood cell production, increased destruction, or chronic blood loss, with the most common forms being anemia of chronic disease (ACD), iron-deficiency anemia (IDA), and megaloblastic anemia. Diagnosis is typically made through laboratory tests such as complete blood count (CBC), iron studies, and vitamin B12/folate levels. Management depends on the underlying cause and may include iron supplementation, erythropoiesis-stimulating agents, vitamin replacement, or blood transfusions. Chronic anemia significantly affects patients' quality of life, underscoring the need for prompt diagnosis and targeted treatment.

Keywords: Anemia of chronic disease (ACD), Iron-deficiency anemia (IDA), Megaloblastic anemia, Red blood cells(RBC), Hepcidin, Inflammation, Erythropoiesis, Iron supplementation, Vitamin B12 deficiency, Folate deficiency, Erythropoiesis-stimulating agents (ESAs),Blood transfusion, Complete blood count (CBC),Ferritin.

Introduction

Pathophysiology of Chronic Anemia Chronic anemia develops due to prolonged disturbances in red blood cell (RBC) production, destruction, or loss, often linked to underlying chronic diseases. The pathophysiology involves a complex interplay of factors, typically categorized into three primary mechanisms: reduced RBC production, increased RBC destruction, or chronic blood loss. The most common types of chronic anemia are Anemia of Chronic Disease (ACD), Iron-Deficiency Anemia (IDA), and Megaloblastic Anemia. Each follows a distinct pathophysiological pathway:

1. Anemia of Chronic Disease (ACD)

ACD is commonly associated with chronic inflammatory conditions such as rheumatoid arthritis, chronic infections, malignancies, or chronic kidney disease. The underlying pathophysiology of ACD is multifactorial:

Inflammation and Cytokine Release: Chronic inflammation leads to increased levels of pro-inflammatory cytokines like interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ).

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Hepcidin Overproduction: IL-6 stimulates the liver to overproduce hepcidin, a key regulator of iron homeostasis. Elevated hepcidin inhibits iron absorption from the intestine and traps iron in macrophages, leading to functional iron deficiency.

Reduced Erythropoiesis: Inflammatory cytokines suppress the production of erythropoietin, a hormone crucial for RBC production in the bone marrow. As a result, erythropoiesis (the process of producing RBCs) is impaired despite normal or slightly reduced iron stores.

Impaired RBC Lifespan: Chronic diseases often shorten the lifespan of RBCs, compounding the anemia.

2. Iron-Deficiency Anemia (IDA)

Iron-deficiency anemia results from inadequate iron availability, which is essential for hemoglobin synthesis. The primary causes of IDA include insufficient iron intake, chronic blood loss, or increased iron demand (e.g., pregnancy). Pathophysiologically, IDA follows a specific trajectory:

Inadequate Iron Supply: Chronic blood loss (e.g., from gastrointestinal bleeding, heavy menstruation, or ulcers) or insufficient dietary intake reduces iron availability for erythropoiesis. Without enough iron, hemoglobin production is impaired, leading to microcytic (small) and hypochromic (pale) RBCs.

Depleted Iron Stores: As iron stores in the liver, spleen, and bone marrow become depleted, the body cannot compensate for the reduced hemoglobin synthesis, exacerbating the anemia.

RBC Morphology Changes: The characteristic finding in IDA is the presence of small, pale RBCs (microcytic, hypochromic anemia), and in severe cases, bone marrow iron stores may be completely exhausted.

3. Megaloblastic Anemia

Megaloblastic anemia occurs due to deficiencies in vitamin B12 or folate, both critical for DNA synthesis and RBC production. The pathophysiology of this condition involves:

DNA Synthesis Impairment: Vitamin B12 and folate are required for thymidine production, a building block of DNA. In their absence, DNA synthesis becomes defective, leading to the production of abnormally large and immature RBC precursors (megaloblasts) in the bone marrow.

Ineffective Erythropoiesis: Despite an increase in RBC precursors, many of these cells are destroyed before they mature due to faulty DNA replication. This leads to an overall reduction in functional RBCs entering circulation.

Neurological Symptoms: In vitamin B12 deficiency, demyelination of nerve fibers occurs due to disrupted fatty acid synthesis, leading to neurological complications alongside anemia.

4. Chronic Blood Loss

Chronic blood loss, such as from gastrointestinal bleeding (ulcers, cancer) or heavy menstrual bleeding, can lead to anemia by continually depleting iron stores. Over time, the body cannot

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

replace lost RBCs fast enough, resulting in a slow decline in hemoglobin and iron levels, eventually causing anemia.

Diagnosis of Chronic Anemia

Clinical presentation (e.g., fatigue, pallor, dyspnea, etc.)
Laboratory tests:
Complete blood count (CBC)
Serum ferritin, transferrin saturation, and iron levels
Vitamin B12, folate levels
Reticulocyte count
Bone marrow biopsy (in specific cases)
Differential diagnosis (e.g., distinguishing chronic anemia from acute anemia, identifying underlying causes)

Management of Chronic Anemia

IronThe management of chronic anemia is centered around treating the underlying cause of the anemia while simultaneously addressing the anemia itself. Treatment strategies depend on the specific type of anemia (e.g., Anemia of Chronic Disease (ACD), Iron-Deficiency Anemia (IDA), Megaloblastic Anemia), as well as the severity and overall health condition of the patient.
Below are key management approaches:

1. Iron Supplementation (For Iron-Deficiency Anemia)

Oral Iron Therapy:

Indication: First-line treatment for patients with iron-deficiency anemia. Oral iron supplements (e.g., ferrous sulfate) are used to replenish iron stores.

Dosage: Typically 100-200 mg of elemental iron daily. The treatment may continue for several months to ensure iron stores are fully restored, even after hemoglobin levels normalize.

Considerations: Common side effects include gastrointestinal disturbances (nausea, constipation). Slow-release formulations or taking iron with food may improve tolerability but may reduce absorption.

Intravenous Iron Therapy:

Indication: Used when oral iron is ineffective, poorly tolerated, or in cases of malabsorption (e.g., inflammatory bowel disease, celiac disease), or when rapid replenishment of iron is needed.

Administration: IV iron (e.g., ferric carboxymaltose, iron sucrose) provides a faster correction of iron deficiency, especially in chronic kidney disease or heart failure patients.
2. Erythropoiesis-Stimulating Agents (ESAs) (For Anemia of Chronic Disease)
Indication:

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Used in chronic conditions like chronic kidney disease (CKD), certain cancers, and inflammatory diseases where anemia persists despite treating the underlying condition.

Mechanism of Action:

ESAs such as recombinant erythropoietin (EPO) or darbepoetin alfa stimulate RBC production in the bone marrow. These agents are often combined with iron supplementation to maximize their efficacy.

Considerations:

Monitoring: Regular monitoring of hemoglobin levels is necessary to avoid excessive erythropoiesis, which can increase the risk of cardiovascular events such as stroke or thrombosis.
Dosage Adjustment: The goal is to maintain hemoglobin levels between 10-12 g/dL, with doses adjusted according to the patient's response.

3. Vitamin B12 and Folate Supplementation (For Megaloblastic Anemia)

Vitamin B12 Supplementation:

Indication: For patients with vitamin B12 deficiency due to malabsorption (e.g., pernicious anemia, post-gastric surgery), B12 supplementation is crucial.

Administration:

Oral B12: For mild cases of deficiency.

Intramuscular (IM) B12 injections: For severe cases or where malabsorption is a concern. IM cyanocobalamin is typically given every day for one week, then weekly for one month, followed by monthly maintenance doses.

Folate Supplementation:

Indication: Used in patients with folate deficiency (e.g., malnutrition, malabsorption, pregnancy).
Dosage: Oral folic acid (1-5 mg daily) is used to restore folate levels and prevent complications.

4. Blood Transfusions

Indication:

Used for patients with severe anemia or wBaxtigul, [15.10.2024 12:30]
The management of chronic anemia is centered around treating the underlying cause of the anemia while simultaneously addressing the anemia itself. Treatment strategies depend on the specific type of anemia (e.g., Anemia of Chronic Disease (ACD), Iron-Deficiency Anemia (IDA), Megaloblastic Anemia), as well as the severity and overall health condition of the patient. Below are key management approaches:

1. Iron Supplementation (For Iron-Deficiency Anemia)

Oral Iron Therapy:

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Indication: First-line treatment for patients with iron-deficiency anemia. Oral iron supplements (e.g., ferrous sulfate) are used to replenish iron stores.
Dosage: Typically 100-200 mg of elemental iron daily. The treatment may continue for several months to ensure iron stores are fully restored, even after hemoglobin levels normalize.

Considerations: Common side effects include gastrointestinal disturbances (nausea, constipation). Slow-release formulations or taking iron with food may improve tolerability but may reduce absorption.

Intravenous Iron Therapy:
Indication: Used when oral iron is ineffective, poorly tolerated, or in cases of malabsorption (e.g., inflammatory bowel disease, celiac disease), or when rapid replenishment of iron is needed.

Administration: IV iron (e.g., ferric carboxymaltose, iron sucrose) provides a faster correction of iron deficiency, especially in chronic kidney disease or heart failure patients.

2**. Erythropoiesis-Stimulating Agents (ESAs)** (For Anemia of Chronic Disease)

Indication:
Used in chronic conditions like chronic kidney disease (CKD), certain cancers, and inflammatory diseases where anemia persists despite treating the underlying condition.

Mechanism of Action:
ESAs such as recombinant erythropoietin (EPO) or darbepoetin alfa stimulate RBC production in the bone marrow. These agents are often combined with iron supplementation to maximize their efficacy.

Considerations:
Monitoring: Regular monitoring of hemoglobin levels is necessary to avoid excessive erythropoiesis, which can increase the risk of cardiovascular events such as stroke or thrombosis.
Dosage Adjustment: The goal is to maintain hemoglobin levels between 10-12 g/dL, with doses adjusted according to the patient's response.

3. Vitamin B12 and Folate Supplementation (For Megaloblastic Anemia)
Vitamin B12 Supplementation:
Indication: For patients with vitamin B12 deficiency due to malabsorption (e.g., pernicious anemia, post-gastric surgery), B12 supplementation is crucial.

Administration:
Oral B12: For mild cases of deficiency.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Intramuscular (IM) B12 injections: For severe cases or where malabsorption is a concern. IM cyanocobalamin is typically given every day for one week, then weekly for one month, followed by monthly maintenance doses.

Folate Supplementation:

Indication: Used in patients with folate deficiency (e.g., malnutrition, malabsorption, pregnancy).
Dosage: Oral folic acid (1-5 mg daily) is used to restore folate levels and prevent complications.

4. **Blood Transfusions**

Indication:

Used for patients with severe anemia or when immediate correction of hemoglobin levels is needed (e.g., severe symptomatic anemia with hemoglobin <7 g/dL or in cases of acute bleeding).
Temporary Measure: Blood transfusions provide quick relief from anemia but are not a long-term solution due to risks like iron overload, immunologic reactions, and infections.

Considerations:

Prevention of Iron Overload: Repeated transfusions can cause iron overload, especially in patients with chronic anemias. Regular monitoring of ferritin levels and the use of iron chelation therapy (e.g., deferoxamine, deferasirox) may be required in such cases.

5**. Addressing the Underlying Cause of Anemia**

Successful management of chronic anemia requires treating the primary condition responsible for the anemia. For example:
Chronic Inflammation: In conditions like rheumatoid arthritis or inflammatory bowel disease, controlling the inflammation with disease-modifying drugs (e.g., methotrexate, biologics) can help reduce anemia.
Chronic Kidney Disease: Managing CKD-related anemia involves optimizing kidney function and using ESAs and iron therapy.
Chronic Blood Loss: Identifying and stopping sources of chronic blood loss, such as gastrointestinal bleeding (from ulcers, malignancy), is essential. This may require endoscopic interventions, surgery, or medications (e.g., proton pump inhibitors).
Nutritional Deficiencies: Improving dietary intake or treating malabsorption (e.g., with gluten-free diets in celiac disease) helps correct anemia caused by nutrient deficiencies.

6. **Lifestyle and Dietary Modifications**

Iron-Rich Diet: Encouraging a diet high in iron (red meat, leafy green vegetables, fortified cereals) can help maintain iron levels, especially in IDA.
Vitamin B12 and Folate Intake: Including foods rich in vitamin B12 (meat, dairy, eggs) and folate (leafy greens, beans, citrus fruits) is important for patients prone to megaloblastic anemia.
Avoiding Inhibitors of Iron Absorption: Advising patients to avoid excessive intake of tea, coffee, or calcium supplements with meals, as these can inhibit iron absorption.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Conclusion

The management of chronic anemia is multifaceted and requires addressing the underlying disease, supplementing deficient nutrients (iron, vitamin B12, folate), and using specific therapies like ESAs or blood transfusions when necessary. Timely intervention and close monitoring can improve patient outcomes and quality of life, reducing the long-term complications of chronic anemia.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5